Brief: Diagnos Reports Extension Of Its Contract With Novo Nordisk
26/04/2022 14:05
April 26 (Reuters) - Diagnos Inc ADK.V :
* DIAGNOS ANNOUNCES EXTENSION OF ITS CONTRACT WITH NOVO
NORDISK
FOR FOLLOW-UP OF DIABETIC PATIENTS UNDER TREATMENT WITH DRUGS
INCLUDED IN ITS THERAPEUTIC PORTFOLIO
Source text for Eikon: ID:nGNX772Lkq
Further company coverage: ADK.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Diagnos
See all newsBrief: Diagnos Submits Modified And Updated Health Canada Licence Application For Cara System Platform
Brief: Diagnos To Submit Future CARA Version To FDA Before End Of Q3
Brief: Diagnos Welcomes Dr. Pierre-Luc Charlebois To Its Advisory Board
Brief: Validated For Global Scale Diagnos Passes Annual MDSAP Audit, Solidifying The Pathway To Approvals With Health Canada & FDA
Brief: Diagnos Provides Update On Its Health Canada Medical Device Licence Application